Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin

Liver Transplantation and Surgery

Volumn 5, Issue 6, 1999, Pages 512-519

  McCaughan, G W ^a   Spencer, J ^a   Koorey, D ^a   Bowden, S ^a   Bartholomeusz, A ^a   Littlejohn, M ^a   Verran, D ^a   Chui, A K K ^a   Ross Sheil, A G ^a   Jones, R M ^a   Locarnini, S A ^a   Angus, P W ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEPATITIS B; HUMAN; IMMUNOTHERAPY; INFECTION PREVENTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT INFECTION;

EID: 0032730424     PISSN: 10743022     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500050601     Document Type: Article

References (35)

1. 1 Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Startzl TE. Orthotopic liver transplantation for patients with hepatitis B virus–related disease. Hepatology 1991 ; 13: 619–626. MEDLINE
2. 2 Lake JR, Wright TL. Liver transplantation for patients with hepatitis B. What have we learned from our results? Hepatology 1991 ; 13: 796–799. MEDLINE
3. 3 Van Thiel DH, Wright HI, Fagciolo S. Liver transplantation for hepatitis B virus–associated cirrhosis: A progress report. Hepatology 1994 ; 20: 20S–23S. MEDLINE
4. 4 Devlin J, Smith HM, Protmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg‐positive liver recipients. J Hepatol 1994 ; 21: 204–210. MEDLINE
5. 5 Samuel D, Bismuth A, Matthieu D, Arulnaden JL, Reynes M, Benhamon JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg‐positive patients. Lancet 1991 ; 337: 813–815. MEDLINE
6. 6 Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. the Investigators of the European Concerted Action on Viral Hepatitis. N Engl J Med 1993 ; 329: 1842–1847. MEDLINE
7. 7 McGory R, Ishitani M, Oliveira W, Stevenson W, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunisation. Transplantation 1996 ; 61: 1358–1364. MEDLINE
8. 8 Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996 ; 24: 1327–1333. MEDLINE
9. 9 Angus P, Locarnini S, McCaughan GW, Jones R, Bowden S. Hepatitis B virus precore mutant infection is associated with severe recurrent disease following liver transplantation. Hepatology 1995 ; 21: 14–18. MEDLINE
10. 10 Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994 ; 58: 719–723.
11. 11 Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ova. J Med Virol 1994 ; 42: 306–310. MEDLINE
12. 12 Lin E, Luscombe C, Wang YY, Shaw T, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus in vivo. Antimicrob Agents Chemother 1996 ; 40: 413–418. MEDLINE
13. 13 Severini A, Liu X‐Y, Wilson JS, Tyrell DLJ. Mechanism of inhibition of duck hepatitis B virus polymerase by(‐)‐βbeta;‐L‐2′,3′‐thiacytidine. Antimicrob Agents Chemother 1995 ; 39: 1430–1435. MEDLINE
14. 14 Dean J, Bowden S, Locarnini S. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with nucleoside analogue ganciclovir. Antiviral Res 1995 ; 27: 171–178. MEDLINE
15. 15 Locarnini S, Guo K, Lucas R, Gust ID. Inhibition of HBV DNA replication by ganciclovir in patients with AIDS. Lancet 1989 ; 2: 1225–1226. MEDLINE
16. 16 Chossegros P, Pouteil‐Noble C, Causse X, Pouyet M, Touraine JL, Trepo C. Ganciclovir is an effective antiviral agent for post transplant chronic HBV infections but maintenance therapy is required. (abstract) J Hepatol 1992 ; 16 (suppl 1): S9.
17. 17 Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995 ; 333: 1657–1661. MEDLINE
18. 18 Yoshida EM, Wolber RA, Mahmood WA, Anderson FH, Scudamore CH, Erb SR. Attempted resolution of acute recurrent hepatitis B in a transplanted liver allograft by the administration of ganciclovir. Transplantation 1994 ; 58: 956–958. MEDLINE
19. 19 Gish RG, Lau J, Brooks L, Fang JWS, Stead S, Imperial JI, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996 ; 23: 1–7. MEDLINE
20. 20 Perillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplant [abstract]. Hepatology 1997 ; 26: 260A.
21. 21 Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 ; 348: 1212–1215. MEDLINE
22. 22 Perillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, et al. Long‐term lamivudine therapy of patients with recurrent hepatitis B post liver transplantation [abstract]. Hepatology 1997 ; 26: 177A.
23. 23 Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996 ; 24: 711–713. MEDLINE
24. 24 Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Brunzendahl H, et al. Hepatitis B resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997 ; 345: 20–22.
25. 25 Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DLJ, Brown N, Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. for the Lamivudine Clinical Investigation Group Hepatology 1998 ; 27: 1670–1677.
26. 26 McMillan JS, Bowden DS, Angus PW, McCaughan GW, Locarnini SA. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology 1996 ; 24: 1371–1378. MEDLINE
27. 27 Naumann U, Protzer‐Knolle U, Berg T, Leder K, Lobed H, Bechstein W, et al. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high‐dose anti‐hepatitis B virus surface antigen immunoprophylaxis. Hepatology 1997 ; 26: 478–484. MEDLINE
28. 28 Jamal H, Regenstein F, Farr G, Perillo RP. Prolonged survival in fibrosing cholestatic hepatitis with long‐term ganciclovir therapy. Am J Gastroenterol 1996 ; 91: 1027–1030. MEDLINE
29. 29 Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones, Locarnini S. Combination antiviral therapy controls severe post liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol 1993 ; 8: 353–357. MEDLINE
30. 30 Boker KH, Ringe B, Kruger M, Pichmayr R, Manns MP. Prostaglandin E plus famciclovir—A new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994 ; 57: 1706–1708. MEDLINE
31. 31 Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997 ; 26: 216–225. MEDLINE
32. 32 Locarnini S. Hepatitis B virus surface antigen and polymerase gene variants—Potential virological and clinical significance. Hepatology 1998 ; 27: 294–297. MEDLINE
33. 33 Tillman HL, Trautwein C, Bock T, Glowenka M, Kruger M, Boker K, et al. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation [abstract]. Hepatology 1997 ; 26: A1202.
34. 34 Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seup Yersiz H, Goss JA, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998 ; 28: 584–589.
35. 35 McCaughan G, Koorey D, Spencer J, Verran D, Chui AKK, Sheil AGR, et al. Prophylactic lamivudine and very low dose HBIG prevent HBV recurrence post liver transplant whilst rescue therapy with lamivudine is associated with significant resistance and graft loss [abstract]. Hepatology 1998 ; 28: 263A.